Vitro Biopharma Inc. entered into definitive agreements with accredited investors for a private placement of a convertible promissory note and warrants to purchase shares of common shares for gross proceeds of $237,600 on March 15, 2023. The note will carry a coupon of 8% per annum, the convertible notes may be converted at any time at the option of the holder and are payable in full at the earliest of the completion of a qualified financing as defined below - a change in control, or an event of default, or the maturity date, which is five years from the date of issuance.